KEA1-97 |
| Catalog No.GC63031 |
KEA1-97 es un disruptor selectivo de la interacciÓn tiorredoxina-caspasa 3 (IC50 = 10 μM). KEA1-97 interrumpe la interacciÓn de la tiorredoxina con la caspasa 3, activa las caspasas e induce la apoptosis sin afectar la actividad de la tiorredoxina.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2138882-71-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
KEA1-97 is a selective Thioredoxin-caspase 3 interaction disruptor (IC50=10 μM). KEA1-97 disrupts the interaction of thioredoxin with caspase 3, activates caspases, and induces apoptosis without affecting thioredoxin activity[1].
KEA1-97 (100 μM; 231MFP cells) impaires thioredoxin pulldown of caspase 3[1].KEA1-97 (10 μM; 48 hours; 231MFP cells) impaires 231MFP serum-free cell proliferation[1].KEA1-97 (10 μM; 0~12 hours; 231MFP cells) activates caspase 3/7 and induces apoptotic cell death[1].KEA1-97 (231MFP cells) resistants to survival and proliferation impairments[1].
KEA1-97 (5 mg/kg; i.p.; 50 days) attenuates tumor xenograft growth[1].
[1]. Anderson KE, et al. Chemoproteomics-Enabled Covalent Ligand Screening Reveals a Thioredoxin-Caspase 3 Interaction Disruptor That Impairs Breast Cancer Pathogenicity. ACS Chem Biol. 2017;12(10):2522-2528.
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *